
Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.

Your AI-Trained Oncology Knowledge Connection!


Sarah Elizabeth Yentz, MD, discusses treatment considerations in patients with favorable-risk renal cell carcinoma.

Sarah Elizabeth Yentz, MD, discusses how she decides between an immunotherapy agent plus a TKI combination vs 2-agent immunotherapy for patients with renal cell carcinoma.

Sarah Elizabeth Yentz, MD, discusses translating data to real-world clinical practice in renal cell carcinoma.

Sarah Elizabeth Yentz, MD, discusses unmet needs in metastatic renal cell carcinoma.

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Published: August 17th 2023 | Updated: